YITAI Pharmatech Co. Ltd, founded in 2006, is a subsidiary of YITAI Group one of major multi-purpose enterprises in China. Yitai Pharmatech Co., Ltd mainly engages in R&D and production of APIs & their intermediates with chiral center. In addition, we provide custom synthesis, FTE and process development. Till now, we’ve already have one R&D center in Beijing, one pilot plant in Hebei, and several GMP cooperative factorys. As we have experienced teams, advanced facilities and our people’s efforts day and night, we´ve already have quite a lot products been finished and put into manufacturing such as Sitafloxacin, Moxifloxacin, Peramivir, Panipenem, Tebipenem, Doripenem, Dorzolamide, Brinzolamide, Bimatoprost, Travoprost, Rizatriptan, Eletriptan, Nebivolol and so on. We are glad to find partners all over the world to better explore this market and share the benefit.
more >
Year of Establishment:
2006
Total Assets(USD):
3,000,000 to 3,999,999
Total Number of Staff:
60 to 69
Main Competitive Advantages:
Other Competitive Advantages:
Patents and Copyrights:
Business Type:
Manufacturer
R&D capacity:
Annual Turnover(USD):
Choose not to disclose
Main Sales Markets:
North America,Central/South America,Western Europe,Asia
Other Competitive Advantages:
Patents and Copyrights:
Six years of qualification
Audited Supplier
Pharma Sources Insight JANUARY 2024
